EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.389
https://www.valueinhealthjournal.com/article/S1098-3015(23)03519-2/fulltext
Section Title :
Section Order :
12413
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03519-2&doi=10.1016/j.jval.2023.09.389